

Elisabetta Barresi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7092207/publications.pdf>

Version: 2024-02-01

47
papers

1,106
citations

304743

22
h-index

414414

32
g-index

47
all docs

47
docs citations

47
times ranked

1467
citing authors

#	ARTICLE	IF	CITATIONS
1	Arylthioamides as H ₂ S Donors: <i>in vitro</i> -Cysteine-Activated Releasing Properties and Vascular Effects in Vitro and in Vivo. <i>ACS Medicinal Chemistry Letters</i> , 2013, 4, 904-908.	2.8	144
2	Apoptosis Therapy in Cancer: The First Single-molecule Co-activating p53 and the Translocator Protein in Glioblastoma. <i>Scientific Reports</i> , 2014, 4, 4749.	3.3	62
3	TSPO ligand residence time: a new parameter to predict compound neurosteroidogenic efficacy. <i>Scientific Reports</i> , 2016, 6, 18164.	3.3	53
4	The Alpha Keto Amide Moiety as a Privileged Motif in Medicinal Chemistry: Current Insights and Emerging Opportunities. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 3508-3545.	6.4	51
5	Iminothioethers as Hydrogen Sulfide Donors: From the Gasotransmitter Release to the Vascular Effects. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 7512-7523.	6.4	48
6	Phenylpyrazolo[1,5- <i>a</i>]quinazolin-5(4 <i>H</i>)-one: A Suitable Scaffold for the Development of Noncamptothecin Topoisomerase I (Top1) Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 7458-7462.	6.4	43
7	Structure-Activity Relationship Refinement and Further Assessment of 4-Phenylquinazoline-2-carboxamide Translocator Protein Ligands as Antiproliferative Agents in Human Glioblastoma Tumors. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 2413-2428.	6.4	41
8	Strategies for the Improvement of Metal-Based Chemotherapeutic Treatments. <i>Biomedicines</i> , 2021, 9, 504.	3.2	35
9	Targeting the 18-kDa translocator protein: recent perspectives for neuroprotection. <i>Biochemical Society Transactions</i> , 2015, 43, 559-565.	3.4	32
10	TSPO PIGA Ligands Promote Neurosteroidogenesis and Human Astrocyte Well-Being. <i>International Journal of Molecular Sciences</i> , 2016, 17, 1028.	4.1	32
11	Deepening the Topology of the Translocator Protein Binding Site by Novel <i>N,N</i> -Dialkyl-2-arylindol-3-ylglyoxydamides. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 6081-6092.	6.4	31
12	Multiple Topoisomerase I (TopoI), Topoisomerase II (TopoII) and Tyrosyl-DNA Phosphodiesterase (TDP) inhibitors in the development of anticancer drugs. <i>European Journal of Pharmaceutical Sciences</i> , 2021, 156, 105594.	4.0	31
13	An update into the medicinal chemistry of translocator protein (TSPO) ligands. <i>European Journal of Medicinal Chemistry</i> , 2021, 209, 112924.	5.5	31
14	3-Aryl-[1,2,4]triazino[4,3- <i>a</i>]benzimidazol-4(10 <i>H</i>)-one: A Novel Template for the Design of Highly Selective A _{2B} Adenosine Receptor Antagonists. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 1490-1499.	6.4	28
15	Modulation of A _{2B} adenosine receptor by 1-Benzyl-3-ketoindole derivatives. <i>European Journal of Medicinal Chemistry</i> , 2013, 69, 331-337.	5.5	28
16	Lead Optimization of 2-Phenylindolylglyoxylyldipeptide Murine Double Minute (MDM)2/Translocator Protein (TSPO) Dual Inhibitors for the Treatment of Gliomas. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 4526-4538.	6.4	28
17	Novel 2-substituted-benzimidazole-6-sulfonamides as carbonic anhydrase inhibitors: synthesis, biological evaluation against isoforms I, II, IX and XII and molecular docking studies. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2019, 34, 1697-1710.	5.2	28
18	Two mixed valence diruthenium(<i>ii</i>),(<i>iii</i>) isomeric complexes show different anticancer properties. <i>Dalton Transactions</i> , 2021, 50, 9643-9647.	3.3	28

#	ARTICLE	IF	CITATIONS
19	Allosteric modulators of human A2B adenosine receptor. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2014, 1840, 1194-1203.	2.4	27
20	A mixed-valence diruthenium(ii,iii) complex endowed with high stability: from experimental evidence to theoretical interpretation. <i>Dalton Transactions</i> , 2020, 49, 14520-14527.	3.3	25
21	Benzofuroxane Derivatives as Multi-Effective Agents for the Treatment of Cardiovascular Diabetic Complications. Synthesis, Functional Evaluation, and Molecular Modeling Studies. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 10523-10531.	6.4	24
22	TSPO ligand residence time influences human glioblastoma multiforme cell death/life balance. Apoptosis: an International Journal on Programmed Cell Death, 2015, 20, 383-398.	4.9	22
23	Unbinding of Translocator Protein 18 kDa (TSPO) Ligands: From in Vitro Residence Time to in Vivo Efficacy via in Silico Simulations. <i>ACS Chemical Neuroscience</i> , 2019, 10, 3805-3814.	3.5	22
24	Sulfonamides incorporating heteropolycyclic scaffolds show potent inhibitory action against carbonic anhydrase isoforms I, II, IX and XII. <i>Bioorganic and Medicinal Chemistry</i> , 2016, 24, 921-927.	3.0	18
25	4-Substituted Benzenesulfonamides Incorporating Bi/Tricyclic Moieties Act as Potent and Isoform-Selective Carbonic Anhydrase II/IX Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 5765-5770.	6.4	18
26	Long lasting MDM2/Translocator protein modulator: a new strategy for irreversible apoptosis of human glioblastoma cells. <i>Oncotarget</i> , 2016, 7, 7866-7884.	1.8	17
27	Carbonic Anhydrase Activators for Neurodegeneration: An Overview. <i>Molecules</i> , 2022, 27, 2544.	3.8	17
28	Targeting the KRAS oncogene: Synthesis, physicochemical and biological evaluation of novel G-Quadruplex DNA binders. <i>European Journal of Pharmaceutical Sciences</i> , 2020, 149, 105337.	4.0	15
29	De novo Neurosteroidogenesis in Human Microglia: Involvement of the 18 kDa Translocator Protein. <i>International Journal of Molecular Sciences</i> , 2021, 22, 3115.	4.1	15
30	Exploiting the 4-Phenylquinazoline Scaffold for the Development of High Affinity Fluorescent Probes for the Translocator Protein (TSPO). <i>Journal of Medicinal Chemistry</i> , 2017, 60, 7897-7909.	6.4	13
31	Novel positive allosteric modulators of A _{2B} adenosine receptor acting as bone mineralisation promoters. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2021, 36, 287-295.	5.2	12
32	Toward PET imaging of A2B adenosine receptors: a carbon-11 labeled triazinobenzimidazole tracer. <i>Nuclear Medicine and Biology</i> , 2016, 43, 309-317.	0.6	10
33	Long lasting inhibition of Mdm2-p53 interaction potentiates mesenchymal stem cell differentiation into osteoblasts. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2019, 1866, 737-749.	4.1	10
34	Residence Time, a New parameter to Predict Neurosteroidogenic Efficacy of Translocator Protein (TSPO) Ligands: the Case Study of <i>N,N</i> -Dialkyl-2-aryldol-3-ylglyoxylamides. <i>ChemMedChem</i> , 2017, 12, 1275-1278.		9
35	Inhibition studies on carbonic anhydrase isoforms I, II, IV and IX with N-arylsubstituted secondary sulfonamides featuring a bicyclic tetrahydroindazole scaffold. <i>European Journal of Medicinal Chemistry</i> , 2021, 220, 113490.	5.5	9
36	Essential Principles and Recent Progress in the Development of TSPO PET Ligands for Neuroinflammation Imaging. <i>Current Medicinal Chemistry</i> , 2022, 29, 4862-4890.	2.4	9

#	ARTICLE	IF	CITATIONS
37	Studies on enantioselectivity of chiral 4-acetylamino-6-alkyloxy-2-alkylthiopyrimidines acting as antagonists of the human A ₃ adenosine receptor. <i>MedChemComm</i> , 2018, 9, 81-86.	3.4	6
38	Novel fluorescent triazinobenzimidazole derivatives as probes for labelling human A1 and A2B adenosine receptor subtypes. <i>Bioorganic and Medicinal Chemistry</i> , 2018, 26, 5885-5895.	3.0	6
39	Benzothiopyranoindole- and pyridothiopyranoindole-based antiproliferative agents targeting topoisomerases. <i>European Journal of Medicinal Chemistry</i> , 2019, 165, 46-58.	5.5	5
40	Allosterism vs. Orthosterism: Recent Findings and Future Perspectives on A2B AR Physio-Pathological Implications. <i>Frontiers in Pharmacology</i> , 2021, 12, 652121.	3.5	5
41	Tetrahydroquinazole-based secondary sulphonamides as carbonic anhydrase inhibitors: synthesis, biological evaluation against isoforms I, II, IV, and IX, and computational studies. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2021, 36, 1874-1883.	5.2	4
42	Translocator Protein 18-kDa: a promising target to treat neuroinflammation-related degenerative diseases. <i>Current Medicinal Chemistry</i> , 2022, 29, .	2.4	4
43	Discovery of Pyrido[3,2- <i>b</i> :5,6]thiopyrano[4,3- <i>d</i>]pyrimidine-Based Antiproliferative Multikinase Inhibitors. <i>ACS Medicinal Chemistry Letters</i> , 2019, 10, 457-462.	2.8	3
44	Carbonic anhydrase activation profile of indole-based derivatives. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2021, 36, 1783-1797.	5.2	3
45	Cancer Immunotherapy: An Overview on Small Molecules as Inhibitors of the Immune Checkpoint PD-1/PD-L1 (2015-2021). <i>Mini-Reviews in Medicinal Chemistry</i> , 2022, 22, .	2.4	3
46	Enriching the Arsenal of Pharmacological Tools against MICAL2. <i>Molecules</i> , 2021, 26, 7519.	3.8	1
47	Drug Repurposing Meets DNA Independent Pathways: Targeting Alternative Substrates for Anticancer Therapy. <i>Current Topics in Medicinal Chemistry</i> , 2021, 21, 2767-2770.	2.1	0